After posting better-than-expected first-quarter results, Regeneron Pharmaceuticals (NASDAQ: REGN) stock enjoyed a nice bounce. The biotech announced solid sales for eye-disease drug Eylea and a strong launch for atopic dermatitis …
Regeneron Pharmaceuticals, Inc. operates as a biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company involves in …
Regeneron Pharmaceuticals (NASDAQ:REGN) has enjoyed a large, five-year 2,000 percent return, and while much is tied to its current growth, the vast majority of Regeneron’s $30 billion market cap is more-so tied to its pipeline. With that …
Transcat Incorporated (NASDAQ:TRNS) had an increase of 3.26% in short interest. Pentwater Management LP holds 1.20 million shares. It is 0.00% or $0 reaching $0 per share. CNH Industrial NV (NYSE:CNHI) has risen 66.12% since June …
SmarTrend identified an Uptrend for Regeneron Pharm (NASDAQ:REGN) on May 2nd, 2017 at $397.84. In approximately 3 months, Regeneron Pharm has returned 28.94% as of today's recent price of $512.96. In the past 52 weeks, shares …
Regeneron Pharmaceuticals Inc. shares surged 6.6% in midday trade Tuesday after Novartis AG released positive data for two late-stage trials comparing its eye disease drug head-to-head with Regeneron's Eylea. The drug, RTH258, met …
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Teva Pharmaceutical (NYSE:TEVA) provided an update on …
Regeneron Pharma stock price ended the last trading day at 466.59. Regeneron Pharma market capitalization is 48.9B and it represents the total market value of REGN stock. A value investor must look at the fundamentals of a stock, and …